Genmab A/S (GMAB)
| Market Cap | 23.83B |
| Revenue (ttm) | 1.43B |
| Net Income (ttm) | 556.46M |
| Shares Out | 653.03M |
| EPS (ttm) | 0.51 |
| PE Ratio | 71.55 |
| Forward PE | 49.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 186,044 |
| Open | 36.57 |
| Previous Close | 37.24 |
| Day's Range | 35.96 - 36.66 |
| 52-Week Range | 26.19 - 49.07 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 37.84 (+3.7%) |
| Earnings Date | Aug 10, 2022 |
About GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL a... [Read more...]
Financial Performance
In 2021, Genmab's revenue was 8.48 billion, a decrease of -16.11% compared to the previous year's 10.11 billion. Earnings were 3.01 billion, a decrease of -36.78%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 35 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is 37.84, which is an increase of 3.70% from the latest price.
News
Transactions in connection with share buy-back program
Company Announcement
Genmab Announces Financial Results for the First Half of 2022
August 10 , 202 2 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022
Genmab Improves Its 2022 Financial Guidance
Company Announcement
Transactions in connection with share buy-back program
Company Announcement
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commerciali...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
Company Announcement
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcorit...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines A...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/R...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluat...
Genmab Commences New Arbitration Under License Agreement With Janssen
Company Announcement
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark ; June 8 , 20 2 2 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will partici...
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical ...
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating t...
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical ...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating t...
Major Shareholder Announcement
Company Announcement
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, wi...
Genmab Announces Financial Results for the First Quarter of 2022
May 11 , 202 2 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022
Should You Buy Genmab (GMAB) Ahead of Earnings?
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
Company Announcement
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of ...
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with ...
- Based on topline results from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities - Data from the clinical trial to be presented at a future...